Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children

Liyuan Chen, Fen Liu, Danna Fang, Jianwei Li · 2023

Read Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children by Liyuan Chen, Fen Liu, Danna Fang, Jianwei Li (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10725990.txt.

Description

Liyuan Chen, Fen Liu, Danna Fang, and Jianwei Li reviewed real-world results for the drug nusinersen in children with spinal muscular atrophy, types two and three. The drug is still fairly new, and most data came from trials. The team studied records of eighteen children treated in twenty twenty-two and twenty twenty-three.

After the loading doses, arm and hand scores improved in nearly half the children. Those who improved most also showed a bigger rise in a key protein in spinal fluid. Liver tests stayed steady. Blood platelet counts and urine protein dipped at times but recovered. The authors call the drug effective and broadly safe, with checks still needed.

Catalog record

CREATORLiyuan Chen, Fen Liu, Danna Fang, Jianwei Li
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE27 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10725990

Browse the full library · About the Tower of Babel